Barclays’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-10,400
Closed -$209K 4845
2020
Q4
$209K Hold
10,400
﹤0.01% 3742
2020
Q3
$254K Hold
10,400
﹤0.01% 3688
2020
Q2
$247K Sell
10,400
-8,400
-45% -$195K ﹤0.01% 3900
2020
Q1
$324K Sell
18,800
-7,100
-27% -$130K ﹤0.01% 3931
2019
Q4
$456K Sell
25,900
-96,900
-79% -$1.64M ﹤0.01% 4380
2019
Q3
$2.17M Sell
122,800
-1,600
-1% -$32.4K ﹤0.01% 2761
2019
Q2
$2.66M Buy
124,400
+75,400
+154% +$1.58M ﹤0.01% 2578
2019
Q1
$1.17M Sell
49,000
-99,700
-67% -$2.27M ﹤0.01% 3235
2018
Q4
$2.92M Buy
148,700
+45,800
+45% +$817K ﹤0.01% 2028
2018
Q3
$1.82M Sell
102,900
-52,100
-34% -$1.02M ﹤0.01% 2992
2018
Q2
$3.34M Buy
155,000
+34,300
+28% +$709K ﹤0.01% 2079
2018
Q1
$2.67M Buy
120,700
+44,800
+59% +$1.24M ﹤0.01% 2189
2017
Q4
$2.31M Sell
75,900
-28,000
-27% -$745K ﹤0.01% 2300
2017
Q3
$2.52M Buy
103,900
+62,400
+150% +$1.66M ﹤0.01% 2122
2017
Q2
$1.02M Buy
41,500
+6,800
+20% +$144K ﹤0.01% 2866
2017
Q1
$752K Sell
34,700
-77,600
-69% -$1.58M ﹤0.01% 2999
2016
Q4
$1.67M Buy
112,300
+1,300
+1% +$18.8K ﹤0.01% 2273
2016
Q3
$1.42M Sell
111,000
-2,600
-2% -$28.1K ﹤0.01% 2292
2016
Q2
$887K Buy
113,600
+95,500
+528% +$550K ﹤0.01% 2720
2016
Q1
$72K Buy
18,100
+6,900
+62% +$29.2K ﹤0.01% 4562
2015
Q4
$56K Sell
11,200
-16,500
-60% -$92.3K ﹤0.01% 4723
2015
Q3
$139K Sell
27,700
-105,400
-79% -$573K ﹤0.01% 4394
2015
Q2
$399K Buy
133,100
+129,800
+3,933% +$422K ﹤0.01% 3652
2015
Q1
$7K Sell
3,300
-110,600
-97% -$257K ﹤0.01% 6415
2014
Q4
$114K Sell
113,900
-1,700
-1% -$2.65K ﹤0.01% 5088
2014
Q3
$115K Buy
115,600
+32,400
+39% +$104K ﹤0.01% 5215
2014
Q2
$250K Sell
83,200
-60,700
-42% -$210K ﹤0.01% 4613
2014
Q1
$432K Buy
143,900
+127,500
+777% +$868K ﹤0.01% 4082
2013
Q4
$98K Sell
16,400
-1,100
-6% -$6.06K ﹤0.01% 5653
2013
Q3
$88K Buy
17,500
+7,700
+79% +$39.9K ﹤0.01% 5708
2013
Q2
$44K Buy
+9,800
New +$46.4K ﹤0.01% 6382

Other funds holding EXEL

Barclays's EXEL Position: Q1 2026 in Review

Barclays reduced its Exelixis (EXEL) stake by 37% in Q1 2026, selling an estimated $12.9M and leaving 504,289 shares worth $21.6M. The position accounts for 0.01% of the portfolio, ranked #1063.

Barclays first reported a position in EXEL in Q2 2013 and has held it in 52 quarters since. The position peaked at $35.3M in Q4 2025. 695 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

  • Barclays held 504,289 shares of Exelixis worth $21.6M as of Q1 2026.
  • Barclays sold 300,762 Exelixis shares in Q1 2026, an estimated $12.9M.
  • Exelixis made up 0.01% of Barclays's portfolio in Q1 2026, its #1063 holding.
  • Barclays first reported a position in Exelixis in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Exelixis position peaked at $35.3M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.